<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">A.C. Tsai</style></author><author><style face="normal" font="default" size="100%">DH Karasic</style></author><author><style face="normal" font="default" size="100%">GP Hammer</style></author><author><style face="normal" font="default" size="100%">ED Charlebois</style></author><author><style face="normal" font="default" size="100%">K. Ragland</style></author><author><style face="normal" font="default" size="100%">AR Moss</style></author><author><style face="normal" font="default" size="100%">JL Sorensen</style></author><author><style face="normal" font="default" size="100%">JW Dilley</style></author><author><style face="normal" font="default" size="100%">D.R. Bangsberg</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Directly Observed Antidepressant Medication Treatment and HIV Outcomes among Homeless and Marginally Housed HIV+ Adults: A Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="default" size="100%">American Journal of Public Health</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year></dates><volume><style face="normal" font="default" size="100%">102</style></volume><pages><style face="normal" font="default" size="100%">forthcoming</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;Objectives.&lt;/b&gt; To determine if directly observed treatment with once-weekly fluoxetine would reduce depression symptom severity and improve HIV outcomes among homeless and marginally housed HIV+ adults. &lt;b&gt;Methods.&lt;/b&gt; This was a non-blinded, randomized controlled trial of 137 HIV+ homeless and marginally housed persons who met DSM-IV criteria for Major Depressive Disorder, Dysthymia, or Minor Depressive Disorder. The intervention was directly-observed once-weekly fluoxetine for 24 weeks, then self-administered once-weekly fluoxetine for 12 weeks. The Hamilton Depression Rating Scale was the primary outcome; response was defined as a 50% reduction from baseline, and remission was defined as a score below 8. Secondary outcome measures were: Beck Depression Inventory-II, antiretroviral uptake, antiretroviral adherence as measured by unannounced pill count, and HIV-1 RNA viral suppression to &amp;lt;50 copies/mL. &lt;b&gt;Results.&lt;/b&gt; The intervention reduced depression symptom severity (b= 1.97; 95% CI, -0.85 to -3.08; P&amp;lt;0.001) and increased response (AOR=2.40; 95% CI, 1.86-3.10; P&amp;lt;0.001) and remission (AOR=2.97; 95% CI, 1.29-3.87; P&amp;lt;0.001). Similar results were obtained with the Beck Depression Inventory-II. No statistically significant differences in secondary HIV outcomes were observed. &lt;b&gt;Conclusions.&lt;/b&gt; Weekly fluoxetine treatment of depression among HIV+ homeless and marginally housed adults resulted in reduced depression symptom severity, but not improved HIV outcomes, over nine months of follow-up.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue></record></records></xml>